Approval · Notice of Compliance 719 · 2002
STARLIX: Notice of Compliance 719
Issued February 13, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 719
- Date
- February 13, 2002
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Oral antidiabetic agent
Products in this notice
Medicinal ingredients
- NATEGLINIDE 60 MG per TAB
- NATEGLINIDE 120 MG per TAB
- NATEGLINIDE 180 MG per TAB